Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 plus pembrolizumab versus pembrolizumab alone in PD-L1-high metastatic NSCLC
NL-OMON60810Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing MK-2870 + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Overall survival. Started May 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60810.